Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

As medicine targets personal DNA profiles, York researchers examine ethics and patient experiences

05.08.2004


Researchers at the University of York are beginning a major study into the ethical and personal issues raised by a potential revolution in healthcare, which could incorporate individualised medical care – pharmacogenetics - into clinical practice.



The use of genetic testing as a routine part of medical treatment opens exciting horizons, but brings with it the responsibility to understand the concerns individuals may have about DNA sampling, and about wider issues such as the possible impact of genetic information. Much of the science of pharmacogenetics is known, but there are many potential hurdles to overcome before the technology is introduced into routine medical use.

Over the next three years Professor Andrew Webster, Dr Graham Lewis and a team in the Science and Technology Studies Unit (SATSU) at York will work with colleagues across the UK monitoring patients’ reactions to warfarin, commonly used to prevent blood clots. The team from York will interview some of the 2,400 patients who will be selected for the study. Of the 2,400 patients, 2000 will be hospital-based and 400 will be recruited through GP surgeries as warfarin can be prescribed by GPs.


Patients’ responses will be mapped against their personal DNA profiles and the SATSU team will interview them to see how they feel about DNA samples being taken, and how publicly acceptable this would be, and the hurdles to introducing the technique.

Warfarin is a very useful drug currently taken by 600,000 patients in the UK, but a small proportion of those who take it suffer serious side effects, even sometimes death. If a patient’s genetic makeup is known beforehand, doctors can prescribe far more accurately so that there are fewer serious side effects.

But the serious ethical issues to be considered, such as reading individual genetic codes from DNA samples, affect both patients and the clinical staff who will have to introduce the new and complex technologies. Clinical staff experiences of these processes are also examined through interviews. Dr Lewis commented; “it is important to study how attitudes and perceptions change with the introduction of new medical technologies like pharmacogenetics, and that means studying the experiences of doctors and nursing staff as well as patients.”

Dr Lewis added: “It’s been known for a long time that an individual’s genetic make-up affects the way they respond to medicines, both in terms of the likelihood of adverse side effects, and whether they respond to treatment. Pharmacogenetics, or so-called personalised medicine, offers the exciting possibility of individualised treatment.

“This could revolutionise medical care, giving doctors the ability to prescribe the best drug for their patient without trial and error. “But there are major considerations – confidentiality, the impact of the genetic information on the patient, and the implications for their families. “We need to understand how people will view this new development.

“There are also cost implications – is it worthwhile introducing pharmacogenetics? There is no real evidence yet from large-scale trials. We need to recognise that many other factors such as diet, lifestyle and age affect a patient’s response to warfarin treatment.”

The genetic profiling of patients taking part in the study will not influence their own treatment but will hopefully help future warfarin users.

The teams involved in the study will share £840,000 in research funding from the Department of Health.

Dr Graham Lewis | alfa
Further information:
http://www.york.ac.uk

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>